Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stockNatural Capsules Ltd (NATCAPSUQ) is currently trading at 159.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Natural Capsules Limited is an established Indian manufacturer of hard capsule shells (gelatin and HPMC), a pioneer of vegetarian capsules in India, and is expanding into steroidal API manufacturing through its subsidiary Natural Biogenex Private Limited, operating two manufacturing plants in Bengaluru and Puducherry and a greenfield API site in Tumkur. Financials show acute short‑term stress: Q3FY26 consolidated revenue of ₹37.75 crore (down 14% YoY) and a PAT loss of ₹7.12 crore, driven by a temporary regulatory shutdown at the Puducherry unit, delayed API fermentation scale up and higher depreciation and finance costs, all of which weighed on margins and cash generation. Strategically significant de‑risking comes from three PLI approvals for niche fermentation‑based steroidal APIs and an expected cumulative incentive of ~₹67 crore over six years, which materially improves the payback profile of the Tumkur API capex and underpins the company’s stated intent to substitute imports for domestic demand. Operational outlook has visible catalysts: the Puducherry plant is operational after regulatory actions were resolved, US tariffs on HPMC capsules have eased restoring export visibility, and management expects shipment spillovers and improved utilisation to drive a meaningful performance rebound in Q4FY26. Natural Capsules Limited retains strong customer relationships (294 customers, 86% repeat business FY25) and diversified export footprint across 28 countries with heavy exposure to Africa (45.6%) and meaningful North American exposure (21.5%), giving both durability and regional concentration risks to monitor.
Over the past 52 weeks, Natural Capsules Ltd has traded between a low of ₹137.50 and a high of ₹296.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Natural Capsules Ltd has a market capitalization of approximately 163.06. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Natural Capsules Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -7.78 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 163.06 Cr, Natural Capsules Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Natural Capsules Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Natural Capsules Ltd is -7.78. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Earnings Transcript
Transcript of Q4 & FY26 earnings call: Q4 revenue Rs.58.45cr (+30% YoY), Q4 EBITDA Rs.1.33cr; FY26 revenue Rs.187.20cr (+11% YoY) with net loss Rs.24.66cr; Tumkur API commercialised, HPMC line commissioned, Puducherry disruption resolved.
Earnings Conference Call
Natural Capsules reported Q4 revenue Rs58.45cr (Q4 YoY +30%) and FY26 revenue Rs187.20cr (FY YoY +11%); FY26 net loss Rs24.66cr (PBT loss Rs27.92cr) with EBITDA loss Rs1.56cr; commercial API sales began, HPMC line commissioned and Fermbox Bio partnership signed.
Bearish
3
Neutral
7
Bullish
4
Bearish
14
Neutral
7
Bullish
25
Bearish
11
Neutral
0
Bullish
21
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Natural Capsules Limited is an established Indian manufacturer of hard capsule shells (gelatin and HPMC), a pioneer of vegetarian capsules in India, and is expanding into steroidal API manufacturing through its subsidiary Natural Biogenex Private Limited, operating two manufacturing plants in Bengaluru and Puducherry and a greenfield API site in Tumkur.
Financials show acute short‑term stress: Q3FY26 consolidated revenue of ₹37.75 crore (down 14% YoY) and a PAT loss of ₹7.12 crore, driven by a temporary regulatory shutdown at the Puducherry unit, delayed API fermentation scale up and higher depreciation and finance costs, all of which weighed on margins and cash generation.
Strategically significant de‑risking comes from three PLI approvals for niche fermentation‑based steroidal APIs and an expected cumulative incentive of ~₹67 crore over six years, which materially improves the payback profile of the Tumkur API capex and underpins the company’s stated intent to substitute imports for domestic demand.
Operational outlook has visible catalysts: the Puducherry plant is operational after regulatory actions were resolved, US tariffs on HPMC capsules have eased restoring export visibility, and management expects shipment spillovers and improved utilisation to drive a meaningful performance rebound in Q4FY26.
Natural Capsules Limited retains strong customer relationships (294 customers, 86% repeat business FY25) and diversified export footprint across 28 countries with heavy exposure to Africa (45.6%) and meaningful North American exposure (21.5%), giving both durability and regional concentration risks to monitor.
Pharmaceuticals & Biotechnology
Pharmaceuticals
166 Cr
Low Risk
-7.9
33.7
—
0.7
296.40
137.50
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
101.15 | 166 Cr | 11.04 | 1.71 | 0.00 | 15.51 | 19.06 | 13.51 | ||
157.00 | 163 Cr | -7.78 | 0.74 | 0.00 | -7.27 | -4.85 | -5.82 | ||
34.25 | 162 Cr | 21.82 | 9.15 | 0.00 | 41.95 | 22.81 | 7.20 | ||
128.60 | 162 Cr | 12.05 | 2.61 | 0.00 | 66.48 | 47.70 | 0.00 | ||
120.15 | 160 Cr | 14.78 | 1.14 | 0.00 | 7.69 | 9.73 | 6.30 | ||
6.59 | 159 Cr | 548.45 | 4.54 | 0.00 | 0.90 | 1.13 | 0.76 | ||
253.00 | 158 Cr | 91.91 | 3.68 | 0.00 | 4.47 | 7.31 | 1.55 | ||
| Median: 7 Co. | — | 120.15 | 162 Cr | 14.78 | 2.61 | 0.00 | 7.69 | 9.73 | 1.55 |
